Literature DB >> 28478516

Tim3+ Foxp3 + Treg Cells Are Potent Inhibitors of Effector T Cells and Are Suppressed in Rheumatoid Arthritis.

Huaqiang Sun1, Wenwu Gao2, Wenping Pan3, Qian Zhang1, Gongteng Wang1, Dapeng Feng4, Xiubin Geng1, Xinfeng Yan1, Shufeng Li5.   

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disorder. Earlier studies have demonstrated that regulatory T (Treg) cells, the main cell type mediating immune tolerance, appeared to be enriched in the inflamed synovial tissues. It is still unclear why the Treg cells in RA patients are unable to limit exacerbated inflammation. Here, we found that the frequency of Tim3+Foxp3+ Treg cells, which were potent suppressors of proinflammatory responses, was downregulated in RA patients. Reduction in Tim3+Foxp3+ Treg frequency was correlated with increased RA disease activity. Furthermore, we observed that Tim3+Foxp3+ Tregs were expressed more interleukin (IL)-10 than Tim3-Foxp3+ Tregs. CD4+CD25+Tim3+ T cells had higher capability of inhibiting interferon (IFN)-γ and tumor necrosis factor (TNF)-α secretion from T cells and peripheral blood mononuclear cells (PBMCs) than CD4+CD25+Tim3- T cells. Compared to that in healthy individuals, CD4+CD25+ T cells in RA patients were less potent in suppressing IFN-γ and TNF-α production from PBMCs. Blocking Tim3 on CD4+CD25+ T cells from healthy controls resulted in an elevation of IFN-γ and TNF-α production from PBMCs, suggesting that Tim3 expression on CD4+CD25+ T cells was required for optimal Treg function. However, this phenomenon was not observed in RA patients. In conclusion, our study suggested that the CD4+CD25+Foxp3+ Treg cells from RA patients demonstrated a reduction of Tim3 and were less functional than Treg cells from healthy controls in a Tim3-related manner.

Entities:  

Keywords:  Tim-3; regulatory T cell; rheumatoid arthritis

Mesh:

Substances:

Year:  2017        PMID: 28478516     DOI: 10.1007/s10753-017-0577-6

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  26 in total

1.  Unmasking the anti-inflammatory cytokine response in rheumatoid synovitis.

Authors:  R Gerli; C Lunardi; C Pitzalis
Journal:  Rheumatology (Oxford)       Date:  2002-12       Impact factor: 7.580

2.  Expression of TIM-3 on CD4+ and CD8+ T cells in the peripheral blood and synovial fluid of rheumatoid arthritis.

Authors:  Shufeng Li; Dayong Peng; Yeteng He; Hu Zhang; Huaqiang Sun; Shiying Shan; Yuanlin Song; Shuzhen Zhang; Hong Xiao; Haihan Song; Ming Zhang
Journal:  APMIS       Date:  2014-02-23       Impact factor: 3.205

3.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors:  Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

Review 4.  tTregs, pTregs, and iTregs: similarities and differences.

Authors:  Ethan M Shevach; Angela M Thornton
Journal:  Immunol Rev       Date:  2014-05       Impact factor: 12.988

5.  Accumulation of FoxP3-expressing CD4+CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis.

Authors:  Z Jiao; W Wang; R Jia; J Li; H You; L Chen; Y Wang
Journal:  Scand J Rheumatol       Date:  2007 Nov-Dec       Impact factor: 3.641

6.  Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells.

Authors:  Anne-Sophie Gautron; Margarita Dominguez-Villar; Marine de Marcken; David A Hafler
Journal:  Eur J Immunol       Date:  2014-06-16       Impact factor: 5.532

7.  Helios expression is a marker of T cell activation and proliferation.

Authors:  Tatiana Akimova; Ulf H Beier; Liqing Wang; Matthew H Levine; Wayne W Hancock
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

8.  TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.

Authors:  Xin Gao; Yibei Zhu; Gang Li; Haitao Huang; Guangbo Zhang; Fengming Wang; Jing Sun; Qianting Yang; Xueguang Zhang; Binfeng Lu
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

9.  Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP.

Authors:  Eyad Elkord; May Abd Al Samid; Belal Chaudhary
Journal:  Oncotarget       Date:  2015-08-21

10.  CD4⁺CD25⁺/highCD127low/⁻ regulatory T cells are enriched in rheumatoid arthritis and osteoarthritis joints--analysis of frequency and phenotype in synovial membrane, synovial fluid and peripheral blood.

Authors:  Babak Moradi; Philipp Schnatzer; Sébastien Hagmann; Nils Rosshirt; Tobias Gotterbarm; Jan Philippe Kretzer; Marc Thomsen; Hanns-Martin Lorenz; Felix Zeifang; Theresa Tretter
Journal:  Arthritis Res Ther       Date:  2014-04-17       Impact factor: 5.156

View more
  15 in total

Review 1.  Treg cells in autoimmunity: from identification to Treg-based therapies.

Authors:  Lisa Göschl; Clemens Scheinecker; Michael Bonelli
Journal:  Semin Immunopathol       Date:  2019-04-05       Impact factor: 9.623

Review 2.  Modulation of regulatory T cell function and stability by co-inhibitory receptors.

Authors:  Liliana E Lucca; Margarita Dominguez-Villar
Journal:  Nat Rev Immunol       Date:  2020-04-08       Impact factor: 53.106

Review 3.  A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.

Authors:  Prabhakaran Kumar; Palash Bhattacharya; Bellur S Prabhakar
Journal:  J Autoimmun       Date:  2018-08-31       Impact factor: 7.094

4.  Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo.

Authors:  Margarita Dominguez-Villar; Khadir Raddassi; Ann Caroline Danielsen; Joseph Guarnaccia; David A Hafler
Journal:  J Autoimmun       Date:  2018-08-16       Impact factor: 7.094

5.  Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.

Authors:  Ayman Oweida; Mohammad K Hararah; Andy Phan; David Binder; Shilpa Bhatia; Shelby Lennon; Sanjana Bukkapatnam; Benjamin Van Court; Nomin Uyanga; Laurel Darragh; Hyun Min Kim; David Raben; Aik Choon Tan; Lynn Heasley; Eric Clambey; Raphael Nemenoff; Sana D Karam
Journal:  Clin Cancer Res       Date:  2018-07-24       Impact factor: 12.531

Review 6.  Antigen-Specific Regulatory T Cell Therapy in Autoimmune Diseases and Transplantation.

Authors:  Claudia Selck; Margarita Dominguez-Villar
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

7.  T-Cell Immune Imbalance in Rheumatoid Arthritis Is Associated with Alterations in NK Cells and NK-Like T Cells Expressing CD38.

Authors:  Hongxing Wang; Kehua Fang; Weining Yan; Xiaotian Chang
Journal:  J Innate Immun       Date:  2021-08-24       Impact factor: 7.111

8.  The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy.

Authors:  Sashi Kandel; Pratik Adhikary; Guangfu Li; Kun Cheng
Journal:  Cancer Lett       Date:  2021-04-22       Impact factor: 9.756

9.  Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer.

Authors:  Jian-Feng Liu; Lei Wu; Lei-Lei Yang; Wei-Wei Deng; Liang Mao; Hao Wu; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  J Exp Clin Cancer Res       Date:  2018-03-05

Review 10.  Control of NK Cell Activation by Immune Checkpoint Molecules.

Authors:  Asma Beldi-Ferchiou; Sophie Caillat-Zucman
Journal:  Int J Mol Sci       Date:  2017-10-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.